Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Trial details
- Registry ID
- NCT06767514
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as KEYTRUDA®
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 | Summit Therapeutics | Phase 3 | Recruiting | 2028-04Estimated |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 | Summit Therapeutics | Phase 3 | Active not recruiting | 2028-12-31Estimated |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinNCT04387461 | CGON | Phase 2 | Completed | 2023-03-07Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |